Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ultragenyx Pharmaceutical Raises FY24 Revenue Guidance From $500M-$530M To $530M-$550M Vs $513.16M Est.

Author: Benzinga Newsdesk | August 01, 2024 04:27pm

2024 Full Year Financial Guidance

Total revenue guidance increased to be in the range of $530 million to $550 million (previously $500 million to $530 million)
Crysvita revenue expected to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.
Dojolvi revenue in the range of $75 million to $80 million
Net Cash Used in Operations less than $400 million

Posted In: RARE